Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib
Many new drugs show promise in the treatment of multiple myeloma (MM); however, their “impact should be measured against the expected outcome in patients failing current therapies.” This study focused on “286 patients with relapsed MM, who were refractory to bortezomib and were relapsed following, refractory to or ineligible to receive, an IMiD (immunomodulatory drug), had measurable disease, and ECOG PS of 0, 1 or 2.” It confirmed that patients experience poor outcomes, once they become refractory to current treatments. Review this study to gain “context for interpreting ongoing trials of new drugs.”
Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P,Siegel D, Blade J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; International Myeloma Working Group.
Click here to view article: